Jumb to content

SCIENTIFIC PUBLICATIONS

On this page you will find an overview of various publications by NADA Germany employees.

If you have any questions, please contact NADA Germany using the contact form:

To contact form

Legal Matters

  • Mortsiefer, L. (2010). Datenschutz im Anti-Doping-Kampf: Grundlagen und Spannungsfelder. Gardez.
  • Mortsiefer, L. (2015). Entwurf eines Gesetzes zur Bekämpfung von Doping im Sport – eine Erläuterung der neuen Vorschriften. SpuRT, 2015(1).
  • Hofmann, K., & Mortsiefer, L. (2016). Verfahrenskostenhilfe in Anti-Doping-Streitigkeiten nach der neuen DIS-Sportschiedsgerichtsordnung. CausaSport, 2016(2).
  • Mortsiefer, L. (2017). Kommentar zum Anti-Doping-Gesetz in Lehner, M., Nolte, M., Putzke, H., Anti-Doping-Gesetz, Handkommentar. Nomos-Verlag.
  • Mortsiefer, L. (2020). Revision des Welt Anti-Doping Code (WADC2021) – Ein Überblick. SpuRT, 2020(1).
  • Mortsiefer, L., (2021). Verfahrensablauf bei CAS und DIS. In Cherkeh, T., Momsen, C., Orth, F., Handbuch Sportstrafrecht. Nomos-Verlag.

Medicine

  • Trinks, S., Scheiff A. B., Knipp, M., Gotzmann, A. (2021). Declaration of Analgesics on Doping Control Forms in German Football Leagues during Five Seasons. German Journal of Sports Medicine / Deutsche Zeitschrift Für Sportmedizin.72(2), 68-73. [More information]
  • Brunschweiger, A., Iqbal, J., Umbach, F., Scheiff, A. B., Munkonda, M.N., Sévigny, J., Knowles, A. F., & Müller, C. E. (2008). Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide.Journal of Medicinal Chemistry., 51(15), 4518-4528. [More information]
  • Borrmann, T., Hinz, S., Bertarelli, D. C., Li, W., Florin, N. C., Scheiff, A. B., & Müller, C. E. (2009). 1-alkyl-8-(piperazine-1-sulfonyl) phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. Journal of Medicinal Chemistry,52(13), 3994-4006. [More information]
  • Scheiff, A. B., Yerande, S. G., El-Tayeb, A., Li, W., Inamdar, G. S., Vasu, K. K., Sudarsanam, V., & Müller, C. E. (2010). 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorganic & Medicinal Chemistry,18(6), 2195-2203. [More information]
  • Scheiff, A. B. (2010). Pharmakologie und Medizinische Chemie Uracil-und Uracilnucleotid-bindender Membranproteine.
  • Baqi, Y., Lee, S. Y., Iqbal, J., Ripphausen, P., Lehr, A., Scheiff, A. B., Zimmermann, H., Bajorath, J., & Müller, C. E. (2010).Development of potent and selective inhibitors of ecto-5′-nucleotidase based on an anthraquinone scaffold. Journal of Medicinal Chemistry,53(5), 2076-2086. [More information]
  • Scheiff, A. B. (2012). Doping im Leistungssport – Was Apotheker wissen sollten. Mitteilungen der Apothekerkammer Niedersachsen, 1, 22-24.  
  • Scheiff, A. B. (2014). Arzneimittel und Doping Aktuelle Aspekte zu Recht und Praxis. PZ PRISMA, 21(4), 201-207.
  • Scheiff, A. B. (2016). Pharmaceuticals and Doping.PHARMAKON,4(1), 22-29. [More information]
  • Scheiff, A. B. (2017). Arzneitherapie bei Sportlern – Was ist erlaubt, was verboten? Pharmazeutische Zeitung, 4, 40-47.
  • Scheiff, A. B. (2018). Aktuelle rechtliche, medizinische und pharmazeutische Aspekte. PZ PRISMA, 25(2), 75-82.
  • Mareck, U., Fusshöller, G., Geyer, H., Huestis, M. A., Scheiff, A. B., & Thevis, M. (2020). Preliminary data on the potential for unintentional antidoping rule violations by permitted cannabidiol (CBD) use. Drug Testing and Analysis. 13(1), 1-11. [More information]
  • Scheiff, A., & Berghoff, T. (2020). Dopingprävention – Was können Sportphysiotherapeuten tun? Sportphysio, 8(02), 94-100.
  • Scheiff, A. (2021). Hormonelle Kinderwunschbehandlung und Verbotsliste der World Anti-Doping Agency (WADA). Gynäkologische Endokrinologie 19, 190–195. [More information]
  • Walpurgis, K., Scheiff, A. B., Welz, M., Müller‐Reul, J., Webborn, N., Görgens, C., Guddat, S., Fußhöller, G., Dib, J. & Thevis, M. (2019). Pilot study on the effects of intravesical oxybutynin hydrochloride instillations on the validity of doping control urine samples. Drug Testing and Analysis, 11(11-12), 1755-1760. [More information]
  • Schölzel, K., Schildberg, F. A., Welz, M., Börner, C., Geiger, S., Kurts, C., Heikenwälder, M., Knolle, P., & Wohlleber, D. (2014). Transfer of MHC-class-I molecules among liver sinusoidal cells facilitates hepatic immune surveillance.Journal of Hepatology,61(3), 600-608. [More information]
  • Welz, M., Demetris, A. J., Heikenwälder, M., Knolle, P. A., & Wohlleber, D. (2014). P149 CROSS-PRESENTATION OF VIRAL ANTIGEN BY LSEC CAN LEAD TO FULMINANT HEPATITIS. Journal of Hepatology, 1(60), 115. [More information]
  • Franken, L., Klein, M., Spasova, M., Elsukova, A., Wiedwald, U., Welz, M., Knolle, P., Farle, M., Limmer, A., & Kurts, C. (2015). Splenic red pulp macrophages are intrinsically superparamagnetic and contaminate magnetic cell isolates. Scientific Reports, 5(1), 1-10. [More information]
  • Höchst, B., Mikulec, J., Baccega, T., Metzger, C., Welz, M., Peusquens, J., Tacke, F., Knolle, P., Kurts, C., & Ludwig-Portugall, I. (2015). Differential induction of Ly6G and Ly6C positive myeloid derived suppressor cells in chronic kidney and liver inflammation and fibrosis.PloS one, 10(3), e0119662. [More information]
  • Schuette, V., Embgenbroich, M., Ulas, T., Welz, M., Schulte-Schrepping, J., Draffehn, A. M., Quast, T., Koch, K., Nehring, M., König, J., Zweynert, A., Harms, F. L., Steiner, N., Limmer, A., Förster, I., Berberich-Siebelt, F., Knolle, P., Wohlleber, D., Kolanus, W., Beyer, M., Schultze, J. L., & Burgdorf, S. (2016). Mannose receptor induces T-cell tolerance via inhibition of CD45 and up-regulation of CTLA-4.Proceedings of the National Academy of Sciences,113(38), 10649-10654. [More information]
  • Hackstein, C. P., Assmus, L. M., Welz, M., Klein, S., Schwandt, T., Schultze, J., Förster, I., Gondorf, F., Beyer, M., Kroy, D., Kurts, C., Trebicka, J., Kastenmüller, W., Knolle, P., & Abdullah, Z. (2017). Gut microbial translocation corrupts myeloid cell function to control bacterial infection during liver cirrhosis.Gut,66(3), 507-518. [More information]
  • Manske, K., Kallin, N., König, V., Schneider, A., Kurz, S., Bosch, M., Welz, M., Cheng, R.‐L., Bengsch, B., Steiger, K., Protzer, U., Thimme, R., Knolle, P. A. & Wohlleber, D. (2018). Outcome of Antiviral Immunity in the Liver Is Shaped by the Level of Antigen Expressed in Infected Hepatocytes. Hepatology, 68(6), 2089-2105. [More information]
  • Welz, M., Eickhoff, S., Abdullah, Z., Trebicka, J., Gartlan, K. H., Spicer, J. A.,  Demetris, A. J., Akhlaghi, H., Anton, M., Manske, K., Zehn, D., Nieswandt, B., Kurts, C., Trapani, J. A., Knolle, P.,  Wohlleber, D., & Kastenmüller, W. (2018).Perforin inhibition protects from lethal endothelial damage during fulminant viral hepatitis.Nature communications,9(1), 1-13.  [More information]
  • Holland, T., Wohlleber, D., Marx, S., Kreutzberg, T., Vento-Asturias, S., Schmitt-Mbamunyo, C., & Welz, M. et al. (2018). Rescue of T-cell function during persistent pulmonary adenoviral infection by Toll-like receptor 9 activation. Journal of Allergy and Clinical Immunology, 141(1), 416-419.